A clinical phase I/II trial of rhIL-4 applied topically in patients with oral squamous cell carcinomas to assess safety and therapeutic activity

Oncology Reports

Volumn 13, Issue 3, 2005, Pages 449-452

  Werkmeister, Richard ^a   Fillies, Thomas ^b   Gaertner, Christoph ^b   Joos, Ulrich ^b   Berdel, Wolfgang E ^b  

^a BUNDESWEHRZENTRALKRANKENHAUS KOBLENZ   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Interleukin 4; Oral squamous cell carcinoma; Topical therapy

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 4;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; MALE; MIDDLE AGED; MOUTH TUMOR; PAIN; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SQUAMOUS CELL CARCINOMA; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-4; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PAIN; TREATMENT OUTCOME;

EID: 15044342068     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.3.449     Document Type: Article

References (22)

1. Clayman GL, Lippman SM, Larmore G, in Holland JF, Frei E Jr, Kufe DW, Morton DL, Weichselbaum RR (eds.). Cancer Medicine (4th ed). Williams & Wilkins, Baltimore, MD, pp1645-1710, 1997.
2. Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
3. Platz H, Fries R and Hudec M: Einfuhrung in die 'Prospektive DÖSAK-Studie' über Plattenepithelkarzinome der Lippen, der Mundhöhle und des Oropharynx. Dtsch Z Mund Kiefer Gesichts Chir 12: 293-302, 1988.
4. Hemprich A, Breier T and Kovács G: Langzeitergebnisse der radikalen Therapie von Plattenepithelkarzinomen der Mundhöhle unter besonderer Berücksichtigung von Spatrezidiven und Zweitmalignomen - eine Katamnese aus 20 Jahren. In: Fortschritte der Kiefer- und Gesichts-Chirurgie. Schwenzer N (ed). Stuttgart, G. Thieme Verlag, New York, pp43-45, 1992.
5. Rassekh CH, Johnson JT and Éibling D: Circulating markers in squamous cell carcinomas of the head and neck: a review. Oral Oncol Eur J Cancer 30: 23-28, 1994. (Pubitemid 24055770)
6. Deleyiannis FWB, Thomas DB, Vaughan TL and Davis S: Alcoholism: independent predictor of survival in patients with head and neck cancer. J Natl Cancer Inst 88: 542-549, 1996. (Pubitemid 26118725)
7. Okada H and Kuwashima N: Gene therapy and biological therapy with interleukin-4. Curr Gene Ther 2: 437-450, 2002.
8. Kawakami K, Leland P and Puri RK: Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res 60: 2981-2987, 2000. (Pubitemid 30395824)
9. Mehrotra R, Varricchio F. Husain SR and Puri RK: Head and neck cancers, but not benign lesions, express interleukin-4 receptors in situ. Oncol Rep 5: 45-48. 1998.
10. Puri RK: Structure and function of interleukin-4 and its receptor. Cancer Treat Res 80: 143-185, 1995.
11. Topp MS, Papadimitriou CA, Eitelbach F, Koenigsmann M, Oelmann E, Koehler B, Oberberg D, Reufi B, Stein H, Thiel E and Berdel WE: Recombinant human interleukin 4 has antiproliferative activity on human cell lines derived from epithelial and nonepithelial histologies. Cancer Res 55: 2173-2176, 1995.
12. Topp MS, Koenigsmann M, Mire-Sluis A, Oberberg D, Eitelbach F, von Marschall Z, Notter M, Reufi B, Stein H, Thiel E and Berdel WE: Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood 82: 2837-2844, 1993. (Pubitemid 23318092)
13. Gooch JL, Lee AV and Yee D: Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 58: 4199-4205, 1998. (Pubitemid 28440580)
14. Leach MW, Rybak ME and Rosenblum IY: Safety evaluation of recombinant human interleukin-4. 11. Clinical studies. Clin Immunol Immunopathol 83: 12-14, 1997. (Pubitemid 27128387)
15. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH and Wagner G: TNM Atlas. Springer, Heidelberg, 1990.
16. Kreuser ED, Fiebig HH, Scheulen ME, Hanauske A, Keppler BK, Mross K, Schalhorn A, Eisenbrand G, Edler L, Höffken K and Berdel WE: Standard operating procedures and organization of German Phase I, II, and III study groups, New Development Group (AWO), and Study Group of Pharmacology in Oncology and Hematology (APOH) of the Association of Medical Oncology (AIO) of the German Cancer Society. Onkologie 21 (suppl 3): 1-70, 1998.
17. Von Hoff DD: He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 82: 96-101, 1990.
18. Myers JN, Yasumura S, Suininami Y, Hirabayashi H, Lin W, Johnson JT, Lotze MT and Whiteside TL: Growth stimulation of head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res 2: 127-135, 1996. (Pubitemid 26042187)
19. Tulpule A, Joshi B, DeGuzman N, Espina BM, Mocharnuk R, Prakash O, Templeton D, Levine AM and Gilll PS: Interleukin-4 in the treatment of AIDS-related Kaposi's sarcoma. Ann Oncol 8:79-83, 1997. (Pubitemid 27112806)
20. Prendiville J, Thatcher N, Lind M, Mcintosh R, Ghosh A, Stern P and Crowther D: Recombinant human interleukin-4 (rhuIL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer - a phase I toxicity study and pharmacokinetic analysis. Eur J Cancer 29A: 1700-1707, 1993. (Pubitemid 23275873)
21. Davis ID, Maher DW, Cebon JS, Green MD, Fox RM, McKendrick JJ, Rybak ME and Boyd AW: A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer. Growth Factors 17: 287-300, 2000. (Pubitemid 30219336)
22. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I and Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-pseudomonas exotoxin in patients with high-grade gliomas. Clin Cancer Res 6: 2157-2165, 2000. (Pubitemid 30399180)